Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

peter french

  • Home
  •  
  • peter french



  • Most Read
  • Latest Comments
  • Promising research for cancer diagnostic tests to be published
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Promising research for cancer diagnostic tests to be published
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Promising research for cancer diagnostic tests to be published
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Promising research for cancer diagnostic tests to be published
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Promising research for cancer diagnostic tests to be published
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch
    CLEO meets with US FDA to develop strategy for ovarian cancer test launch
    • News

  • Rhythm Biosciences nears commercialisation of revolutionary cancer test following filing of approval documents with the TGA
    Rhythm Biosciences nears commercialisation of revolutionary cancer test following filing of approval documents with the TGA
    • News

  • Theranos, but make it legit.. Does this company have the answer to cancer detection via blood test?
    Theranos, but make it legit.. Does this company have the answer to cancer detection via blood test?
    • News

  • Universal Biosensors partners with Peter Mac for handheld cancer diagnosis device
    Universal Biosensors partners with Peter Mac for handheld cancer diagnosis device
    • News

  • How BCAL Diagnostics is improving minimally invasive methods of early cancer detection
    How BCAL Diagnostics is improving minimally invasive methods of early cancer detection
    • News

  • Promising research for cancer diagnostic tests to be published
    • News

    Promising research for cancer diagnostic tests to be published

    Sadly, 1 in 7 women will be diagnosed with breast cancer at some stage in their life. That’s 1 in 7 mothers, daughters, aunties, girlfriends, wives, friends and nieces.  In the last 10 years, breast cancer diagnosis has increased by 36% and remains the second most common cause of death from cancer among females.  Health

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.